Results 231 to 240 of about 89,614 (291)

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

open access: yesBritish Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Obesity is associated with an altered baseline and post-vaccination influenza antibody repertoire

open access: yes, 2021
Alhadi MA   +10 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

MAFF Suppresses Necroptosis in Pancreatic Cancer via the GATA4‐MLKL Axis

open access: yesCancer Science, EarlyView.
MAFF promotes pancreatic cancer progression by acting as a transcriptional repressor of the GATA4‐MLKL axis, thereby inhibiting necroptotic cell death. This study identifies the MAFF‐GATA4‐MLKL pathway as a novel therapeutic target and a significant prognostic biomarker for pancreatic adenocarcinoma.
Xinwei Zhou   +3 more
wiley   +1 more source

RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation

open access: yesCancer Science, EarlyView.
RASD2 drives clear cell renal cell carcinoma (ccRCC) progression by physically interacting with RAF1 to induce its Ser338 phosphorylation, which subsequently activates the P38/ERK–MAPK signaling pathway to promote malignant tumor phenotypes and poor prognosis.
Jingxuan Yu   +10 more
wiley   +1 more source

Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire

open access: yes, 2021
Melani RD   +25 more
europepmc   +1 more source

KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2‐Dependent MDSC Recruitment

open access: yesCancer Science, EarlyView.
KPNA2 drives intratumoral MDSC accumulation and immunosuppression in ovarian cancer via the NF‐κB/CCL2/CCR2 axis. Mechanistically, KPNA2 facilitates NF‐κB/p65 nuclear translocation and induces CCL2 transcription, recruiting MDSCs to establish an immunosuppressive microenvironment.
Qingli Li   +8 more
wiley   +1 more source

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

open access: yesClinical &Experimental Allergy, EarlyView.
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy